Protagonist Therapeutics, Inc.
NASDAQ:PTGXBiotechnology
+$1.72 today
- Market cap
- $8.30B
- Beta
- 1.83
- P/E (TTM)
- -64.2
- EPS (TTM)
- -$1.76
Volume 0.43M
Average 0.72M
PTGX Operating Cash Flow
Cash generated by the company's core business operations during the period.
Protagonist Therapeutics, Inc.NASDAQ: PTGX
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow turns positive
Q2 FY2026 operating cash flow was $219.05M, compared with -$28.78M a year earlier. Trailing-twelve-month operating cash flow was $131.2M.
Context
- Operating cash flow amounted to 125.3% of revenue in FY2025, up 82.9 pp from a year earlier.
- Operating cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly operating cash flow holds near $219.05M or moves back toward the trailing-twelve-month quarterly average of $32.8M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 57.67M USD
- Year-over-year change
- -68.7%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 57.67M | -68.7% |
| FY2024 | 2024-12-31 | 184.15M | +362.2% |
| FY2023 | 2023-12-31 | (70.24M) | +35.0% |
| FY2022 | 2022-12-31 | (108.14M) | -0.3% |
| FY2021 | 2021-12-31 | (107.87M) | — |
Operating Cash Flow vs competitors
How PTGX compares with its peers on the latest reported figures
- PTGX's LTM Jun 2026 operating cash flow of $131.2M is the 4th largest of the 7 companies compared; the peer median is $135.64M.
- Its year-over-year change of +231.8% is the 2nd highest of 7, against a peer median of +34.7%.
- Operating cash flow amounts to 46.5% of revenue for PTGX, versus a peer median of 449.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $395M | -8.3% | +29.4% | 5567.4% | |
| LTM Sep 2026 | $249.32M | +54.0% | +28.3% | 275.5% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $189.94M | +15.3% | +62.2% | — |
| LTM Jun 2026 | $131.2M | +231.8% | — | 46.5% | |
| LTM Mar 2026 | $81.33M | -1.5% | +9.6% | — | |
| LTM Mar 2026 | $52.21M | +323.8% | -11.3% | 623.9% | |
| LTM Mar 2026 | $4.48M | +104.1% | — | 1.9% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding PTGX) | $135.64M | +34.7% | +28.3% | 449.7% | |
Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.55M) | (127.39M) | (78.96M) | 275.19M | (130.15M) |
| Depreciation & Amortization | 2.78M | 3.37M | 3.31M | 2.96M | 1.28M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.4M | 24.2M | 29.29M | 37.55M | 45.97M |
| Change in Working Capital | (3.31M) | (7.77M) | (19.51M) | (122.61M) | 146.21M |
| Accounts Receivables | (915K) | 4.24M | (9.99M) | (155M) | 164.88M |
| Inventory | 915K | (4.24M) | 0 | 0 | 0 |
| Accounts Payables | (1.39M) | 2.05M | (2.87M) | 842K | 3.72M |
| Other Working Capital | (1.92M) | (9.81M) | (6.65M) | 31.55M | (22.39M) |
| Other Non-Cash Items | 1.83M | (549K) | (4.38M) | (8.94M) | (5.64M) |
| Operating Cash Flow | (107.87M) | (108.14M) | (70.24M) | 184.15M | 57.67M |
| Capital Expenditures | (1.1M) | (795K) | (609K) | (1.36M) | (1.59M) |
| Acquisitions (Net) | 14.76M | (91.47M) | 0 | 0 | 0 |
| Purchases of Investments | (286.59M) | (214.87M) | (191.05M) | (621.7M) | (546.59M) |
| Sales of Investments | 271.83M | 307.14M | 152.4M | 323.57M | 498.84M |
| Other Investing Activities | (14.76M) | 91.47M | 0 | 0 | 0 |
| Investing Cash Flow | (15.86M) | 91.47M | (39.26M) | (299.48M) | (49.33M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 123.83M | 14.55M | 132.1M | 26.45M | 23.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.09M | 4.29M | 38.38M | (600K) | (479K) |
| Financing Cash Flow | 129.92M | 18.84M | 170.48M | 25.85M | 22.86M |
| Effect of Forex Changes | (126K) | (90K) | 0 | 0 | (62K) |
| Net Change in Cash | 6.07M | 2.08M | 60.98M | (89.48M) | 31.14M |
| Free Cash Flow | (108.97M) | (108.93M) | (70.85M) | 182.8M | 56.08M |
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
Intrinsic Alpha fair value
Locked
Current Price
$127.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.